ScholarIQanswers from OpenAlex & ORCID
Paulo M. Hoff
ResearcherPublications, citations & collaboration network
Paulo M. Hoff is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Paulo M. Hoff have?
ScholarIQindexed works
Paulo M. Hoff has 549 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Paulo M. Hoff have?
ScholarIQcitation count
Paulo M. Hoff has 25,697 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Paulo M. Hoff?
ScholarIQh-index
Paulo M. Hoff has an h-index of 67 in OpenAlex.
What is the i10-index of Paulo M. Hoff?
ScholarIQi10-index
Paulo M. Hoff has an i10-index of 215 in OpenAlex.
What is the ORCID of Paulo M. Hoff?
ScholarIQorcid
The ORCID for Paulo M. Hoff is on the source record.
What is the OpenAlex record for Paulo M. Hoff?
ScholarIQopenalex
The OpenAlex for Paulo M. Hoff is on the source record.
What are the most-cited papers on Paulo M. Hoff?
ScholarIQmost cited works
Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases
Jean‐Nicolas Vauthey, Timothy M. Pawlik, Dario Ribero, Tsung‐Teh Wu, Daria Zorzi, Paulo M. Hoff, Henry Q. Xiong, Cathy Eng, Gregory Y. Lauwers, Mari Mino–Kenudson, Mauro Risio, Andrea Muratore, Lorenzo Capussotti, Steven A. Curley, Eddie K. Abdalla
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M. Swain, David Miles, Sung‐Bae Kim, Young‐Hyuck Im, Seock‐Ah Im, Semiglazov Vf, Eva Ciruelos, Andreas Schneeweiß, Sherene Loi, Estefanía Monturus, Emma Clark, Adam Knott, Eleonora Restuccia, Mark Benyunes, Javier Cortés, Richy Agajanian, Rizvana Ahmad, Bahriye Aktas, Victor Hugo Medeiros Alencar, Dino Amadori, Jurandyr Moreira de Andrade, Fábio Franke, Catia Angiolini, Kenjiro Aogi, Jess F. Armor, Wichit Arpornwirat, L. Assersohn, William Audeh, Walter E. Aulitzky, Sérgio Jobim Azevedo, Maria Alejandra Bartoli, Norberto Batista López, María Inés Bianconi, Laura Biganzoli, Ruemu Birhiray, Marianna Bitiņa, Ron Blachy, Kimberly Blackwell, Rita A. Blanchard, Paulette Blanchet, Ion Boiangiu, B. Bower, Christine Brezden‐Masley, Adam Brufsky, Leanne S. Budde, Priscilla B. Caguioa, Lourdes Calvo, Mario Campone, Robert R. Carroll, Hugo R. Castro, Valorie F. Chan, Veena Charu, Saverio Cinieri, Michael Clemens, Emilio Alba Conejo, Eduardo Côrtes, Bruno Coudert, Eduardo Cronemberger, Daniel de Iracema Gomes Cubero, Shaker R. Dakhil, Brooke Daniel, Neville Davidson, Maria de Fátima Dias Gauí, Susana de la Cruz, María del Pilar, G. Delgado, John Ellerton, César Estuardo, Louis Fehrenbacher, Jean-Marc Ferrero, Patrick J. Flynn, Małgorzata Foszczyńska‐Kłoda, Sandra Franco, Hirofumi Fujii, Chris Gallagher, Teresa Gamucci, N Giacomi, Miguel Gil Gil, Antonio González-Martı́n, Vera Gorbunova, E. Gotovkin, Nathan Green, Elza Grincuka, Eva‐Maria Grischke, Vincent Hansen, Jeffrey B. Hargis, Maik Hauschild, Roberto Hegg, Carolyn B. Hendricks, Róbert Hermann, Paulo M. Hoff, Jun Horiguchi, Javier Hornedo Muguiro, Stefano Iacobelli, Kenichi Inoue, Gustavo Ismael, Yoshinori Itoh, Dr Hiroji Iwata, D Jendiroba, Rosa Jochim
Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas
Maria A. Kouvaraki, Jaffer A. Ajani, Paulo M. Hoff, Robert A. Wolff, Douglas B. Evans, Richard D. Lozano, James C. Yao
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Scott Kopetz, Paulo M. Hoff, Jeffrey S. Morris, Robert A. Wolff, Cathy Eng, Katrina Y. Glover, R. Adinin, Michael J. Overman, V VALERO, Sijin Wen, Christopher H. Lieu, Shaoyu Yan, Hai T. Tran, Lee M. Ellis, James L. Abbruzzese, John V. Heymach